The optimal antithrombotic regimen in peripheral arterial disease (PAD) is not known, leading to significant variations in antithrombotic treatment protocols in randomized trials and clinical practice. In device trials, antithrombotic regimens in patients receiving peripheral vascular interventions have not been clearly reported on. This review summarizes and discusses the most recent evidence on this topic to provide a potential guide to clinical practice.
Methods:
A search of the literature was done for publications that reported outcomes of major PAD device trials. Reported outcomes and various antithrombotic regimens were studied.
Results:
Use of antithrombotic therapy varied significantly between various device trials. Reporting of antithrombotic regimens at the time of follow-up is lacking.
Conclusion:
Outcome data on optimal antithrombotic regimens are presently lacking largely due to the significant heterogeneity and underreporting of antithrombotic regimens at follow-up among prior clinical trials. Standardization and reporting of precise antithrombotic regimens at various points of follow-up in device trials of patients with PAD should be attempted so as to minimize differences in treatment patterns when evaluating new devices.
SawJBhattDLMoliternoDJ. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol. 2006;48(8):1567–1572.
4.
HirschATHaskalZJHertzerNR. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006;47(6):1239–1312.
5.
CacoubPPBhattDLStegPGTopolEJCreagerMA; CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;30(2):192–201.
6.
BonacaMPBhattDLStoreyRF. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol. 2016;67(23):2719–2728.
7.
SecemskyEAYehRWKereiakesDJ. Extended duration dual antiplatelet therapy after coronary stenting among patients with peripheral arterial disease: a subanalysis of the dual antiplatelet therapy study. JACC Cardiovasc Interv. 2017;10(9):942–954.
8.
NorgrenLHiattWRDormandyJA. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–S67.
9.
SmithSCJrBenjaminEJBonowRO. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–2473.
10.
Society for Vascular Surgery Lower Extremity Guidelines Writing Group, ConteMSPomposelliFBClairDG. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015;61(3 suppl):2S–41S.
11.
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.
12.
FowkesFGRPriceJFStewartMC. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303(9):841–848.
13.
BelchJMacCuishACampbellL. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
14.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329–1339.
15.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329–1339.
16.
HiattWRFowkesFGHeizerG. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376(1):32–40.
17.
TricociPMHuangMSZHeldC. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366:20–33.
18.
BonacaMPSciricaBMCreagerMA. Vorapaxar in patients with peripheral artery disease: results from TRA2P-TIMI 50. Circulation. 2013;127(14):1522–1529, 1529e1-1529e6.
19.
BonacaMPGutierrezJACreagerMA. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50 (TRA2P-TIMI 50). Circulation. 2016;133(10):997–1005.
20.
JonesWSTricociPHuangZ. Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). Am Heart J. 2014;168(4):588–596.
21.
EikelboomJWConnollySJBoschJ. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–1330.
22.
PatelMRBeckerRCWojdylaDM. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: data from the PLATO trial. Eur J Prev Cardiol. 2015;22(6):734–742.
23.
LingHAndrewsEOmbengiDLiF. Extended duration dual antiplatelet therapy after percutaneous coronary intervention in patients with peripheral arterial disease: a meta-analysis. Cardiol Res Pract. 2018;9(3):137–143.
24.
SodenPAZettervallSLUlteeKHJ. Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization. J Vasc Surg. 2016;64(6):1633–1644.e1.
25.
Warfarin Antiplatelet Vascular Evaluation Trial Investigators, AnandSYusufSXieC. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357(3):217–227.
26.
CapellWHBonacaMPNehlerMR. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in Endovascular or surgical limb Revascularization for Peripheral Artery Disease (VOYAGER PAD). Am Heart J. 2018;199:83–91.
27.
Gerhard-HermanMDGornikHLBarrettC. 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;69:1465–1508.
28.
AboyansVRiccoJBBartelinkM. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39(9):763–816
29.
Alonso-CoelloPBellmuntSMcGorrianC. Antithrombotic therapy in peripheral artery disease. Chest. 2012;141(2 suppl):e669S–e690S.
30.
GremmelTXheliliESteinerSKoppensteinerRKoppCWPanzerS. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: differences between peripheral and coronary angioplasty. Atherosclerosis. 2014;232(1):119–124.
31.
BelchJJDormandyJ; CASPAR Writing Committee. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52(4):825–833, 833.e1-866.e2.
32.
StroblFFBrechtelKSchmehlJ. Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease. J Endovasc Ther. 2013;20(5):699–706.
33.
TepeGBantleonRBrechtelK. Management of peripheral arterial interventions with mono or dual antiplatelet therapy—the MIRROR study: a randomized and double-blinded clinical trial. Eur Radiol. 2012;22(9):1998–2006.
34.
RobertsonLGhouriMAKovacsF. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev. 2012;(8):CD002071.
35.
MollFBaumgartnerIJaffM. Edoxaban plus aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD trial. J Endovasc Ther. 2018;25(2):158–168.
36.
MangiacapraFBartunekJBijnensN. Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. J Thromb Haemost. 2012;10(12):2452–2461.
37.
RamaiahVGammonRKieszSResults of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trialMidterm outcomes from the TALON Registry: treating peripherals with SilverHawk: outcomes collection. J Endovasc Ther. 2006;13(5):592–602.
38.
McKinseyJFZellerTRocha-SinghKJ; DEFINITIVE LE Investigators. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv. 2014;7(8):923–933.
39.
SchwindtAGBennettJGJrCrowderWH. Lower extremity revascularization using optical coherence tomography-guided directional atherectomy: final results of the eValuatIon of the pantheriS optical cOherence tomography imagiNg atherectomy system for use in the peripheral vasculature (VISION) study. J Endovasc Ther. 2017;24(3):355–366.
40.
CioppaAStabileEPopusoiG. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: one-year single centre clinical results. Cardiovasc Revasc Med. 2012;13(4):219–223.
41.
SixtSRastanABeschornerU. Acute and long-term outcome of Silverhawk assisted atherectomy for femoro-popliteal lesions according the TASC II classification: a single-center experience. Vasa. 2010;39(3):229–236.
42.
ZellerTLanghoffRRocha-SinghKJ. Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: twelve-month results of the DEFINITIVE AR study. Circ Cardiovasc Interv. 2017;10(9):e004848.
43.
ShammasNW. Current role of atherectomy for treatment of femoropopliteal and infrapopliteal disease. Interv Cardiol Clin. 2017;6(2):235–249.
44.
AdamsGLMustaphaJGrayW. The LIBERTY study: design of a prospective, observational, multicenter trial to evaluate the acute and long-term clinical and economic outcomes of real-world endovascular device interventions in treating peripheral artery disease. Am Heart J. 2016;174:14–21.
45.
DasTMustaphaJIndesJ. Technique optimization of orbital atherectomy in calcified peripheral lesions of the lower extremities: the CONFIRM series, a prospective multicenter registry. Catheter Cardiovasc Interv. 2014;83(1):115–122.
46.
ShammasNWLamRMustaphaJ. Comparison of orbital atherectomy plus balloon angioplasty vs. balloon angioplasty alone in patients with critical limb ischemia: results of the CALCIUM 360 randomized pilot trial. J Endovasc Ther. 2012;19(4):480–488.
47.
DattiloRHimmelsteinSICuffRF. The COMPLIANCE 360° trial: a randomized, prospective, multicenter, pilot study comparing acute and long-term results of orbital atherectomy to balloon angioplasty for calcified femoropopliteal disease. J Invasive Cardiol. 2014;26(8):355–360.
48.
BabaevAZavlunovaSAttubatoMJMartinsenBJMintzGSMaeharaA. Orbital atherectomy plaque modification assessment of the femoropopliteal artery via intravascular ultrasound (TRUTH Study). Vasc Endovascular Surg. 2015;49(7):188–194.
LairdJRZellerTGrayBH. Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the LACI multicenter trial. J Endovasc Ther. 2006;13(1):1–11.
51.
DaveRMPatlolaRKollmeyerK. Excimer laser recanalization of femoropopliteal lesions and 1-year patency: results of the CELLO registry. J Endovasc Ther. 2009;16(6):665–675.
52.
DippelEJ. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovasc Interv. 2015;8(1 pt A):92–101.
53.
GandiniRDel GiudiceCMerollaSMorosettiDPampanaESimonettiG. Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drug-eluting balloon angioplasty in patients with critical limb ischemia: a single-center, prospective, randomized study. J Endovasc Ther. 2013;20(6):805–814.
54.
ZellerTKrankenbergHSteinkampH. One-year outcome of percutaneous rotational atherectomy with aspiration in infrainguinal peripheral arterial occlusive disease: the multicenter pathway PVD trial. J Endovasc Ther. 2009;16(6):653–662.
55.
DavisTRamaiahVNiaziKMartin GisslerHCrabtreeT. Safety and effectiveness of the phoenix atherectomy system in lower extremity arteries: early and midterm outcomes from the prospective multicenter EASE study. Vascular. 2017;25(6):563–575.
56.
GarciaLARosenfieldKRMetzgerCD. SUPERB final 3-year outcomes using interwoven nitinol biomimetic supera stent. Catheter Cardiovasc Interv. 2017;89(7):1259–1267.
57.
AggarwalVWaldoSWArmstrongEJ. Endovascular revascularization for aortoiliac atherosclerotic disease. Vasc Health Risk Manag. 2016;12:117–127.
58.
PowellRJJaffMRSchroëHBenkoADiaz-CartelleJMüller-HülsbeckS. Stent placement in the superficial femoral and proximal popliteal arteries with the innova self-expanding bare metal stent system. Catheter Cardiovasc Interv. 2017;89(6):1069–1077.
59.
LairdJRKatzenBTScheinertD. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery. Circ Cardiovasc Interv. 2010;3(3):267–276.
60.
LammerJZellerTHauseggerKA. Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial. Cardiovasc Intervent Radiol. 2015;38(1):25–32.
61.
OhkiTKichikawaKYokoiH. Outcomes of the Japanese Multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions. J Vasc Surg. 2017;66(1):130–142.e1.
62.
LammerJZellerTHauseggerKA. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol. 2013;62(15):1320–1327.
63.
Müller-HülsbeckSKeirseKZellerTSchroëHDiaz-CartelleJ. Twelve-month results from the MAJESTIC trial of the eluvia paclitaxel-eluting stent for treatment of obstructive femoropopliteal disease. J Endovasc Ther. 2016;23(5):701–707.
64.
DakeMDAnselGMJaffMR. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4(5):495–504.
65.
GrayWAKeirseKSogaY. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet. 2018;392(10157):1541–1551. doi:10.1016/S0140-6736(18)32262-1
66.
MuldowneyJASIIIStringhamJRLevySE. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler Thromb Vasc Biol. 2007;27(2):400–406.
67.
GongoraCAShibuyaMWesslerJD. Impact of paclitaxel dose on tissue pharmacokinetics and vascular healing. JACC Cardiovasc Interv. 2015;8(8):1115–1123.
68.
TepeGLairdJSchneiderP. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131(5):495–502.
69.
RosenfieldKJaffMRWhiteCJ. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373(2):145–153.
70.
SchroederHWernerMMeyerDR. Low-dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease. Circulation. 2017;135(23):2227–2236.
71.
SteinerSWillfort-EhringerASievertH. 12-Month results from the first-in-human randomized study of the ranger paclitaxel-coated balloon for femoropopliteal treatment. JACC Cardiovasc Interv. 2018;11(10):934–941.
72.
KatsanosKSpiliopoulosSKitrouPKrokidisMKarnabatidisD. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(24):e011245.
73.
SchneiderPALairdJRDorosG. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis. J Am Coll Cardiol. 2019.
74.
Office of the Commissioner. FDA in Brief: FDA alerts health care professionals of possible increased risk of death associated with specific drug-containing balloons and stents in certain patients with peripheral arterial disease. Office of the Commissioner. https://www.fda.gov/NewsEvents/Newsroom/FDAInBrief/ucm629613.htm. (2019, Accessed February 9, 2019).
